

NCPE Annual Symposium

2020

From Evidence to Access

Pharmacoeconomics in the Irish Healthcare Setting

6-7 May 2020
Dublin Castle



DAY ONE

Registration and tea/coffee on arrival from 8.15

Opening Address	<i>Paul Reid, Director General of HSE</i>	9.00
Session 1 – Stakeholder Perspectives on HTA	<i>Moderated by Dr Roisin Adams</i>	9.30-11.00
National Centre for Pharmacoeconomics	<i>Prof Michael Barry, Director of NCPE</i>	
Irish Pharmaceutical Healthcare Association	<i>Paul Reid, IPHA Vice President (Managing Director, Pfizer)</i>	
Healthcare Payer Perspective	<i>Shaun Flanagan, Head of Primary Care Reimbursement Service</i>	
<i>Panel Discussion</i>		
Coffee break		11.00-11.30
Session 2 - Fair Pricing of Medicines	<i>Moderated by Caitriona ni Choitir</i>	11.30-13.00
Waiting Lists & the Cost-effectiveness Threshold	<i>Dr James O'Mahony, Assistant Professor, Public Health & Primary Care, Trinity College Dublin</i>	
Opportunity Cost	<i>Dr Cormac Kennedy, Assistant Professor, School of Medicine, Trinity College Dublin</i>	
Indication Based Pricing	<i>Helen O'Donnell, NCPE</i>	
<i>Panel Discussion</i>		
Lunch		13.00-14.00
Session 3 – International Perspectives and Early Evidence	<i>Moderated by Dr Cara Usher</i>	14.00-16.00
International Horizon Scanning Initiative / BeNeLuxA	<i>Dr Roisin Adams, NCPE</i>	
EUnetHTA Relative Effectiveness Assessments	<i>Dr Emer Fogarty, NCPE</i>	
Evidence in the Era of Early Approval of Medicines	<i>Dr Aisling O'Leary, NCPE</i>	
<i>Panel Discussion</i>		
Afternoon Close		16.00

NCPE Annual Symposium 2020

From Evidence to Access
Pharmacoeconomics in the Irish Healthcare Setting

6-7 May 2020
Dublin Castle



DAY TWO

Registration and tea/coffee on arrival from 8.15

Session 1 – Innovation in the Absence of Evidence *Moderated by Dr Aisling O’Leary* **9.00-11.00**

Challenges of Early Evidence *Denis Lacombe, EORTC Director General*

Clinician Perspective *Prof Maeve Lowery, Professor of Translational Cancer Medicine, Trinity College Dublin*

Patient Perspective *Eric Lowe OBE, Former Chief Executive of Myeloma UK*

Trial design – Regulatory vs HTA requirements *Prof Cathal Walsh, Chair in Statistics, University of Limerick*

Panel Discussion

Coffee Break **11.00-11.30**

Session 2 – Update on HTA and Rapid Review Process *Moderated by Dr Emer Fogarty* **11.30-13.00**

HTA Assessments and Rapid reviews – Key Trends and Challenges *Dr Lesley Tilson, NCPE*

Elicitation of Clinical Opinion *Niamh Carey, NCPE*

Companion Diagnostics in HTA Submissions *Dr Aine Varley, NCPE*

TBC *Dr Cara Usher, NCPE*

Panel Discussion

Lunch **13.00-14.00**

Session 3 - NCPE Review Group Discussion *Moderated by Dr Laura McCullagh* **14.00-15.00**

Issues Arising from HTA Submissions to NCPE *Members of the NCPE Review Group*

Session 4 – Medicines Management Programme **15.00-16.00**

Update from the MMP *Prof Michael Barry and members of the MMP team*

Closing Remarks **Professor Michael Barry** **16.00**